BCL2L1 and triple-negative breast carcinoma: Together, our data suggest that targeting NF-κB activation reduces the expression of its target genes (e.g., CD44, BCL-XL,and cMyc) and subsequently affects proliferation and invasiveness of triple negative breast cancer cells.